Coronavirus vaccine in China produces neutralizing antibodies in early-stage trial

Advertisement

BEGIN ARTICLE PREVIEW:

An engineer shows a plastic model of the Covid-19 coronavirus at the Quality Control Laboratory at the Sinovac Biotech facilities in Beijing.Nicolas Asfouri | AFP | Getty ImagesA potential coronavirus vaccine developed in China appeared to provoke neutralizing antibodies in dozens of patients in an early-stage clinical trial, an important step in developing a vaccine that might provide immunity to Covid-19.The vaccine candidate also induced binding antibodies in most of the patients within 28 days and appeared to be safe and well-tolerated, according to the findings of the phase one trial published Friday in The Lancet.”These results represent an important milestone,” Wei Chen, a professor at the Beijing Institute of Biotechnology and who led the study, said in a press release. “However, these results should be interpreted cautiously. The challenges in the development of a Covid-19 vaccine are unprecedented, and the ability to trigger these immune responses does not necessarily indicate that the vaccine will protect humans from Covid-19.”The potential vaccine from CanSino Biologic, called Ad5-nCoV, was approved for human trials in March. The participants were ages 18 to 60 and received a low, medium or high dose. There were 36 people in each of the three groups of low, medium …

END ARTICLE PREVIEW

READ MORE FROM SOURCE ARTICLE